About this trial
Background and Objectives Hospital at Home (HaH) delivers hospital-level treatment to acutely ill patients in their own homes, including daily medical and nursing visits, infusions, physiotherapy, and diagnostics. It bridges inpatient and outpatient care, working closely with hospitals, office-based physicians, home care services (Spitex), and therapy providers.
There are two main pathways:
Admission Avoidance: stable patients requiring hospitalization are admitted directly to HaH instead of an inpatient ward.
Early Supported Discharge: patients treated in hospital are discharged earlier than usual and transferred to HaH.
Evidence International studies show HaH to be safe and effective. Reviews report comparable mortality and rehospitalization, shorter hospital stays, and cost advantages. Admission avoidance is linked to trends toward lower mortality and costs. Research showed similar mortality but fewer rehospitalizations, longer treatment duration, and reduced risks of institutionalization, depression, and anxiety. HaH patients were older, with reduced daily living activities, yet care costs were on average USD 5,054 lower than inpatient care.
In Switzerland, the mean hospital stay in 2019 was 8 days (acute somatic: 5.2; psychiatry: 33.5).
Study Hypotheses
HaH can be delivered at equal or lower cost than regular hospitalization.
HaH care is safe, with few complications, and yields high patient satisfaction.
Study Objective To demonstrate that hospital-equivalent home treatment of acutely ill patients is effective, appropriate, cost-efficient (according to Swiss WZW criteria), safe, and associated with high satisfaction and low complication rates compared with inpatient care.
Endpoints
Primary: Costs - HaH vs. inpatient care at Hirslanden Clinic, using REKOLE® cost accounting.
Secondary: Mortality, therapy type, monitoring, diagnostics, rehospitalization, complications, satisfaction, patient-reported outcomes, length of stay, referrals to nursing homes, follow-up after discharge, ED visits, rehabilitation referrals, and home care type.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Inpatients in the hospital or patients in Hospital at Home care
Age ≥ 18 years
Admission due to a typical Hospital at Home diagnosis (mild to moderate inflammatory and infectious diseases of the lungs, urinary tract, gastrointestinal tract, heart, and skin; exacerbated chronic obstructive pulmonary disease; exacerbation of chronic heart failure; wounds; bleeding/anemia; dehydration; deterioration of general condition in multimorbid patients; infection-related complications in oncological patients; psychiatric problems including delirium; metabolic or autoimmune diseases; orthopedic patients; pain exacerbations of any cause; palliative patients up to and including terminal situations)
Patients without severe cognitive impairment or dysfunction who are capable of providing informed consent and/or completing the questionnaire
Disqualifiers
Inpatient admission for other reasons
Refusal to provide informed consent
Trial population
200 participants total, 100 from the regular hospital ("brick and mortar"), 100 from Hospital at Home. Patients from 18years of age upwards with a disease treated in the hospital or in hospital at home.
Trial design
Case-control
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Costs
Comparison of cost of treatment in Hospital at Home vs. regular hospital ("brick and mortar"). Data will be collected via financal data of both groups, 100 patients from the regular hospital (Klinik Hirslanden Zurich) and 100 patients from Hospital at Home AG (Zollikon)
Secondary outcomes
Effectiveness (clinical outcome)
Measure of how effective the treatment in Hospital at Home vs. regular hospital ("brick and mortar") is. The clinical outcome will be measured by: Mortality up to 30 days after discharge, emergency-admission up to 30 days after discharge, readmission to the hospital/H@H up to 30 days after discharge, GP-consultation up to 30 days after discharge, specialist-consultation up to 30 days after discharge, admission to nursing home up to 30 days after discharge. Data will be collected through patient data, collected via clinical information system and phone calls to the patient 30 days after discharge.
Effectivness (complications)
Measure of how effective the treatment in Hospital at Home vs. regular hospital ("brick and mortar") is. The clinical outcome will be measured by measuring the number and kind of complication. We will collect data regarding number of falls, (up to 30 days after discharge), number of new infections during treatment, development of bedsores during treatment (yes/no), development of delirium during treatment (yes/no), thrombosis during treatment (yes/no). Data will be collected through patient data, collected via clinical information system and phone calls to the patient 30 days after discharge.
Patient satisfaction
How satisfied are the patients treated in Hospital at Home compared to patients treated in the regular hospital ("brick and mortar"), measured by patient questionnaires. First questionnaire (patient satisfaction) consists of 8 questions each reaching from 0-5 points (0 = worst, 5 = best) regarding overall assessment, recommendation of service, assessment by relatives, competencies of nurses, competencies of doctors, quality of hotline, satisfaction with communication/flow of information and safety. Second questionnaire ist the PROMIS Globla health 10 consisting of 10 questions, first 9 reaching from 1-5, last question reaching from 0-10 points. The questions assess global well-being, quality of life, physical and psychological well-being, satisfaction with level of activity, handling of everyday activities, handling of everyday phsysical tasks, mental problems, tiredness, pain. Data will be collected through patient data, collected via clinical information system and phone calls.
Other outcomes
patient data
Data regarding demographics including name, date of birth, age, sex, language, distance hospital to home, date of death, date of admission/discharge, length of stay, ICD-codes, -chapters, major diagnostic chapters, type of insurance, billing, referrer, living situation (alone yes/no), care situation (independent, nursing home), nr of drugs ad admission/30d post discharge, polypharmacy (defined as \>5 drugs at admission), nr of chronic comorbidities, Charlson comorbidity score/-10 year survival rate, cognitive impairment (yes/no), i.v.-medication during treatment (yes/no, duration), monitoring (yes/no, duration), nr of hotline calls/ringing of nurse, nr of doctor/nurses visits, nr of ecg/sonography/xray/expert consultation, yes/no of physiotherapy/O2-substitution. Data will be collected through patient data, collected via clinical information system and phone calls to the patient 30 days after discharge.
result of first blood sample
Collection of results of first blood sample, taken at admission to hospital/H@H. Collection of white blood cell count G/l, hemoglobin g/l, CRP mg/l, natrium mmol/l, potassium mmol/l, creatinine umol/l, GFR ml/min/1.73m2, ALT U/l. Data will be collected through patient data, collected via clinical information system and phone calls to the patient 30 days after discharge.
first vital signs measured at admission
Collection of values of first vital sign measurement at admission. Collection of SpO2 in %, body temperature in °C, blood pressure in mmHg, respiratory rate in x/min. Data will be collected through patient data, collected via clinical information system and phone calls to the patient 30 days after discharge.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Hospital at Home AG
Lead sponsor
Klinik Hirslanden, Zurich
Collaborator